RxDoctor Payments Data

Randall Berliner, MD

Neurology · Bronx, NYNPI 1962469809

Payments from drug & device makers

$192,000in general payments, 2019–2025

Across 1,299 payments — averaging $147.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$75K
  • Teva Pharmaceuticals USA, Inc.$28K
  • Acadia Pharmaceuticals Inc$24K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$20K
  • Amgen$15K
  • Lilly USA, LLC$13K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$4,7133%
  • Speaking & faculty fees$111,12175%
  • Travel & lodging$5,7324%
  • Food & beverage$26,12518%
  • Education$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)398$75,218
Teva Pharmaceuticals USA, Inc.137$27,996
Acadia Pharmaceuticals Inc23$24,039
Otsuka Pharmaceutical Development & Commercialization, Inc.1$20,350
Amgen(2 entities)50$15,346
Lilly USA, LLC53$13,144
Lundbeck LLC56$2,901
MDD US Operations, LLC18$926
Otsuka America Pharmaceutical, Inc.40$915
Novartis48$876
Pfizer47$858
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)29$714
Avanir Pharmaceuticals, Inc.29$598
Amneal Pharmaceuticals LLC28$581
AstraZeneca(2 entities)24$568
EMD Serono, Inc.21$558
Kyowa Kirin, Inc.25$551
Neurocrine Biosciences, Inc.15$447
SK Life Science, Inc.15$353
Takeda Pharmaceuticals U.S.A., Inc.14$297
UCB, Inc.16$288
Biogen14$288
GE HealthCare10$243
Adamas Pharmaceuticals, Inc.14$237
Eisai Inc.9$205
Genentech USA, Inc.9$201
Currax Pharmaceuticals LLC16$193
Argenx US, Inc.9$188
Neurelis, Inc.6$165
Biohaven Pharmaceuticals, Inc.10$164
Vanda Pharmaceuticals Inc.10$158
Alkermes, Inc.6$152
Mallinckrodt Enterprises LLC5$152
Supernus Pharmaceuticals, Inc.5$146
Scilex Pharmaceuticals Inc.8$139
Grifols USA, LLC6$134
Neuronetics, Inc.4$118
Axsome Therapeutics, Inc.3$109
Abbott5$102
Johnson & Johnson3$93
Sunovion Pharmaceuticals Inc.4$85
Idorsia Pharmaceuticals US Inc4$82
Sanofi3$74
Averitas Pharma Inc.2$69
Bristol Myers Squibb5$67
Sumitomo Pharma America, Inc.3$60
Baxter Healthcare1$55
Collegium Pharmaceutical, Inc.1$52
Vertical Pharmaceuticals, LLC3$50
Biohaven Pharmaceutical Holding Company Ltd.2$49
CSL Behring2$47
Acorda Therapeutics, Inc2$47
Life Molecular Imaging Ltd1$46
Corium, LLC2$44
Upsher-smith Laboratories LLC3$43
Alfasigma USA, Inc.3$41
Almatica Pharma LLC2$40
Strongbridge US Inc.2$39
Bausch Health US, LLC2$33
Revance Therapeutics, Inc.1$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$192,000 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$412,576
Medicare patients
150
Services billed
24,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant113$161,787
BotoxOnabotulinumtoxina96$122,331
NuplazidPimavanserin Tartrate20$87,755
QuliptaAtogepant72$84,120
Nurtec OdtRimegepant Sulfate36$73,351
Emgality PenGalcanezumab-Gnlm63$52,925
VraylarCariprazine Hcl25$38,822
Ajovy SyringeFremanezumab-Vfrm16$25,625
Aimovig AutoinjectorErenumab-Aooe19$22,793
Diclofenac Sodium20$12,039
Emgality SyringeGalcanezumab-Gnlm14$9,552
Aripiprazole57$7,511
BelsomraSuvorexant17$6,751
Duloxetine Hcl208$3,556
Bupropion XlBupropion Hcl132$3,050

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Botox, Qulipta, Vraylar$75,218$407,060306 claims
Acadia Pharmaceuticals IncNuplazid$24,039$87,75520 claims
PfizerNurtec Odt$858$73,35136 claims
Upsher-smith Laboratories LLCTopiramate$43$65647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →